Recent Updates
Recently added Catalysts
ZYME

Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa ® (Tucatinib) and Chemotherapy

Wednesday, July 28, 2021 1 min read
Key Takeaway: Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa ® (Tucatinib) and Chemotherapy

Full Press Release Details

Zymeworks Announces First Patient with Advanced HER2-Positive Breast Cancer Dosed with Zanidatamab in Combination with Tukysa ® (Tucatinib) and Chemotherapy.
Tags: ZYME Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jul 28, 2021